Reference : Impact of glucose-lowering therapies on risk of stroke in type 2 diabetes.
Scientific journals : Article
Human health sciences : Pharmacy, pharmacology & toxicology
Human health sciences : Endocrinology, metabolism & nutrition
http://hdl.handle.net/2268/216136
Impact of glucose-lowering therapies on risk of stroke in type 2 diabetes.
English
Bonnet, Fernand mailto [Centre Hospitalier Universitaire de Rennes > > > >]
Scheen, André mailto [Université de Liège > Département des sciences cliniques > Département des sciences cliniques >]
2017
Diabetes and Metabolism
Yes (verified by ORBi)
International
1262-3636
1878-1780
France
[en] Antidiabetic agents ; Clinical trial ; Comprehensive review ; Stroke ; Type 2 diabetes
[en] Patients with type 2 diabetes (T2D) have an increased risk of stroke compared with people without diabetes. However, the effects of glucose-lowering drugs on risk of ischaemic stroke in T2D have been less extensively investigated than in coronary heart disease. Some evidence, including the UKPDS, has suggested a reduced risk of stroke with metformin, although the number of studies is limited. Inhibition of the KATP channels increases ischaemic brain lesions in animals. This is in agreement with a recent meta-analysis showing an increased risk of stroke with sulphonylureas vs. various comparators as both mono- and combination therapy. Pioglitazone can prevent recurrence of stroke in patients with previous stroke, as already shown in PROactive, although results are less clear for first strokes. As for DPP-4 inhibitors, there was a non-significant trend towards benefit for stroke, whereas a possible increased risk of stroke with SGLT2 inhibitors-and in particular, empagliflozin in the EMPA-REG OUTCOME trial-has been suggested and requires clarification. Experimental results support a potential protective effect of GLP-1 receptor agonists against stroke that has, at least in part, been translated to clinical benefits in T2D patients in the LEADER and SUSTAIN-6 trials. Further interventional studies are now warranted to confirm the effects of glucose-lowering agents on risk of stroke in patients with T2D. In summary, the effects of antidiabetic drugs on risk of stroke appear to be heterogeneous, with some therapies (pioglitazone, GLP-1 receptor agonists) conferring possible protection against ischaemic stroke, other classes showing a neutral impact (DPP-4 inhibitors, insulin) and some glucose-lowering agents being associated with an increased risk of stroke (sulphonylureas, possibly SGLT2 inhibitors, high-dose insulin in the presence of insulin resistance).
http://hdl.handle.net/2268/216136
10.1016/j.diabet.2017.04.004
Copyright (c) 2017 Elsevier Masson SAS. All rights reserved.

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Restricted access
2017 Stroke risk AHAs Scheen Bonnet 0517.pdfPublisher postprint596.88 kBRequest copy

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.